Tirzepatide for metabolic dysfunction-associated steatohepatitis: results from phase II clinical trials and perspectives

While these results suggest a potential role for tirzepatide in MASH treatment given its ability to improve insulin sensitivity and reduce food intake, factors already shown to be beneficial in reducing livers steatosis and fibrosis, larger clinical trials are needed.